Spago Nanomedical and Charles River Laboratories announce agreement forpreclinical studies of SpagoPix
Spago Nanomedical has selected Charles River Laboratories, a leading global CRO, to conduct regulatory preclinical toxicology and safety studies of SpagoPix before clinical trials.
The SpagoPix project is advancing towards clinical trials and the product candidate SN132D has shown good effect and safety in pilot tests. The agreement with Charles River covers GLP-studies aiming for generation of regulatory toxicity and safety data that are required for initiation of first-in-man studies.
Production of SN132D to cater for the amounts needed in the regulatory preclinical program is ongoing. The program will commence during the summer and is expected to be ongoing for approximately 7 months.
”We are looking forward to initiate the regulatory preclinical program with Charles River to prepare for clinical trials with SN132D in the best way possible. The clinical program is expected to commence during 2018”, says Mats Hansen, CEO of Spago Nanomedical.
”Our leading team of safety assessment experts is looking forward to collaborating with Spago Nanomedical to progress SN132D through a regulatory preclinical program,” said William Barbo, Corporate Executive Vice President & Chief Commercial Officer at Charles River.
For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, email@example.com.
Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.
SpagoPix is a contrast agent based on nanoparticles and manganese aiming to improve cancer diagnostics using magnetic resonance imaging (MRI). By offering high precision and excellent signal amplification in tumors and metastases correct diagnosis of cancer with MRI is facilitated. Improved diagnostic capabilities may increase the chances of efficient treatment for the patients.
Tumorad® is a further development of the company´s proprietary nanoparticles with the purpose of delivering radionuclides for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer.
The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on 25 January, 2017.
For further information, see www.spagonanomedical.se.